Search clinical trials for: Secukinumab (AIN457) 150 mg s.c.

Total 2300 results

Novartis Pharmaceuticals

Completed

Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM)

Ankylosing Spondylitis

Germany
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)

Spondylitis, Ankylosing

Germany, Austria, Denmark, United States, Australia, Netherlands, Poland, Italy, Bulgaria, Spain, Russian Federation, United Kingdom, Greece, Czechia, Canada, Norway, Slovakia, Switzerland, Finland
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Psoriatic Arthritis

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)

Anklyosing Spondylitis

Germany, Austria, Spain, Switzerland, United Kingdom, United States, Singapore, Russian Federation, Netherlands, Italy, Finland, Czechia, Canada
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

Moderate to Severe Palmoplantar Psoriasis

Belgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission (GigAINt)

Giant Cell Arteritis

Germany
Novartis Pharmaceuticals

Completed

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap)

Ankylosing Spondylitis

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Plaque Psoriasis

China, Thailand, Philippines, Turkey, Hungary, Malaysia
Novartis Pharmaceuticals

Completed

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

Psoriatic Arthritis

United Kingdom, Belgium, Germany, Thailand, Israel, United States, Philippines, Singapore, Italy, Argentina, Russian Federation, Bulgaria, Czechia, Australia, Canada, Poland, Brazil, Slovakia
Novartis Pharmaceuticals

Withdrawn

An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound (INTERCEPT)

Psoriasis
Tongji Hospital
Wuhan Central Hospital; Wuhan Hospital of Traditional Chinese Medicine

Recruiting

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

Ankylosing Spondylitis (AS)

China
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Japan
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH)

Polymyalgia Rheumatica

United States, Australia, Germany, Belgium, France, Spain, Italy, Lebanon, Switzerland, Japan, Israel, Argentina, Netherlands, Colombia, Chile, Hungary, Poland, Turkey, Czechia, Brazil, South Africa, Mexico, Canada, Denmark, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
Novartis Pharmaceuticals

Recruiting

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Giant Cell Arteritis | Polymyalgia Rheumatica

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Novartis

Completed

Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis (MoA aIL-17)

Spondylarthropathies

Netherlands
Novartis Pharmaceuticals

Terminated

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)

Lupus Nephritis

China, Croatia, Czechia, Russian Federation, Turkey, Australia, Spain, Thailand, Argentina, United States, Denmark, Greece, Romania, Germany, Korea, Republic of, India, Brazil, Japan, Peru, Portugal, Italy, Taiwan, Vietnam, Norway, Colo... and more
Novartis Pharmaceuticals

Completed

Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (SIGNATURE)

Psoriasis

United Kingdom, Ireland
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA)

United States, Austria, Spain, Greece, Hungary, Turkey, France, Israel, Australia, Belgium, Germany, Argentina, United Kingdom, Brazil, Chile, Portugal, Bulgaria, Czechia, Guatemala, Italy, Switzerland, Denmark, Poland, Estonia, Finland, Russian... and more
Novartis Pharmaceuticals

Completed

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (VIP-S)

Chronic Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S)

Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). (SUNSHINE)

Hidradenitis Suppurativa

United States, Spain, Russian Federation, Taiwan, Germany, France, United Kingdom, Korea, Republic of, Japan, Australia, Switzerland, Austria, Italy, Sweden, India, Israel, Mexico, Philippines, Portugal, Turkey, Greece, Hungary, Bul... and more
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis (PREVENT)

Non-radiographic Spondyloarthritis

United States, Spain, Belgium, Hungary, Turkey, Netherlands, Austria, Israel, Sweden, Switzerland, Germany, Korea, Republic of, Australia, Russian Federation, Italy, Portugal, United Kingdom, Bulgaria, France, Czechia, Poland, Japan, Mexi... and more
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Ankylosing Spondylitis

India, Turkey, Belgium, Thailand, United States, Czechia, Greece, Russian Federation, Bulgaria, Guatemala, Italy, Korea, Republic of, Malaysia, Sweden, Colombia, Philippines, Poland, Brazil
Novartis Pharmaceuticals

Terminated

A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) (ORBIT)

Thyroid Eye Disease | Graves Orbitopathy

Germany
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis

Non-radiographic Axial Spondyloarthritis

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
Novartis Pharmaceuticals

Completed

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. (PROSE)

Plaque Psoriasis

Germany, United Kingdom, Belgium, Czechia, Estonia, Italy, France, Israel, Spain, Bulgaria, Lithuania, Portugal, Poland, Romania, Latvia, Greece, Slovakia
Novartis Pharmaceuticals

Active, not recruiting

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

Psoriasis

Argentina, Canada, Guatemala, Mexico, Brazil, Costa Rica, Dominican Republic, Panama
Novartis Pharmaceuticals

Terminated

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. (REASSURE2)

Rheumatoid Arthritis

United States, Germany, Greece, Argentina, Brazil, Colombia, Czech Republic, Dominican Republic, Guatemala, India, Italy, Japan, Korea, Republic of, Panama, Portugal, South Africa
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy (UnchAIN)

Tendinopathy

Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Ankylosing Spondyloarthritis

United Kingdom, Korea, Republic of, China, Czechia
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Novartis Pharmaceuticals

Completed

Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis

Chronic Plaque Psoriasis
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

Psoriatic Arthritis

United States, India, Greece, Thailand, Czechia, Philippines, Bulgaria, Russian Federation, Guatemala, South Africa, Malaysia, Colombia, Brazil, Poland, Turkey
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents (REASSURE)

Rheumatoid Arthritis

Colombia, United States, Belgium, Turkey, Thailand, Argentina, Italy, Guatemala, India, Japan, Panama, Hungary, United Kingdom, Mexico, Puerto Rico, Canada
Novartis Pharmaceuticals

Completed

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Chronic Plaque-type Psoriasis

Germany, United States, Japan, France, Israel, Norway, Iceland
Novartis Pharmaceuticals

Completed

Extension in AS: Sustainability of Benefits, Safety and Tolerability (MEASURE 1 ext)

Spondylitis, Ankylosing

Belgium, Germany, Netherlands, France, United States, Bulgaria, Italy, Mexico, Russian Federation, Peru, United Kingdom, Turkey, Canada, Taiwan
Novartis Pharmaceuticals

Completed

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Dry Eye

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

Moderate to Severe Plaque-type Psoriasis

United States, Colombia, Estonia, Japan, Taiwan, Israel, Canada, Lithuania, Argentina, Latvia, Iceland, Mexico
Novartis Pharmaceuticals

Completed

Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg (OFM ISF)

Healthy | Psoriasis

Austria
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriatic Arthritis

United States, United Kingdom, India, Austria, Denmark, Netherlands, Spain, Germany, Thailand, Israel, Argentina, Greece, Philippines, Latvia, Italy, Guatemala, Russian Federation, Hungary, Ireland, Vietnam, Czechia, Canada, Sweden, M... and more
Novartis Pharmaceuticals

Completed

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus (PRELUDE)

Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris

Germany, United States, France
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Novartis Pharmaceuticals

Active, not recruiting

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Juvenile Psoriatic Arthritis | Enthesitis Related Arthritis

South Africa, Italy, Belgium, Russian Federation, Turkey, Germany, Spain, Poland, United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis (SCALP)

Chronic Scalp Psoriasis

United States
Novartis Pharmaceuticals

Completed

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) (SUPREME)

Plaque Type Psorisis

Italy

Search clinical trials for: Secukinumab (AIN457) 150 mg s.c.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations